3 results
The HOPE-3 trial will evaluate the effects of lipid modification with rosuvastatin and of blood pressure lowering with candesartan/hydrochlorothiazide (HCT) and their combination in a wide range of middle aged people, who are at average risk for…
Our hypothesis is that continuous intravenous glucose monitoring is helpful in ICU patients treated with IIT to:a) reach and maintain the glucose-target of 4.4-6.1 mmol/L soonerb) to increase safety, by eliminating the development of hypoglycaemiac…
Number of patients with >=80% reduction of VT burden, i.e., any ICD-treated or highly-symptomatic VT episodes, at one year after STAR compared to the year before (including VTs during the 8 week-blanking period). Efficacy parameters will be…